journal article·2023

Bioinspired immuno-radio-enhancers toward synergistic nanomedicine through radiation-induced abscopal effects and immunocheckpoint blockade therapies

Pengfei Zhang, Hu Chen, Chuan Chen, Xuan Liu, Hongwei Cheng, Yaming Wu, Xiaoyong Wang, Gang Liu, Yun Zeng

Biomaterials Science· Volume 11· Issue 22
Publisher page

Abstract

Local radio-therapy combined with immunotherapy has attracted great interest in controlling local tumors. In this study, we have developed membrane-cloaked manganese dioxide nanoparticles displaying anti-PD-L1 antibodies as targeted immuno-radio-enhancers. Mediated by anti-PD-L1 antibodies (aPD-L1) expressed on cell membranes, this kind of membrane-coated nanosystem can selectively deliver cytosine-phosphate-guanine (CpG)-loaded MnO2 nanoparticles (NPs) and induce systemic anti-tumor immunities, thereby achieving favorable immuno/radio-therapeutic outcomes. Through expressing various functional proteins onto cellular membranes, the new class of membrane-camouflaged nanovehicles can be endowed with a wide variety of artificial functionalities such as enzymatic catalytic capabilities and specific targeting. This versatile nanoplatform, in general, enables the targeted delivery of theranostics, opening a new avenue for personalized nanomedicine.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Radiation Therapy and Dosimetry · Radiopharmaceutical Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, Xiamen Medical College, Xiamen 361023, China

Institute of Molecular Immunology, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510000, China

State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen 361002, China

Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM) & Amoy Hopeful Biotechnology Co., Ltd, Xiamen 361027, China

Funding

National Natural Science Foundation of China · National Key Research and Development Program of China · Fundamental Research Funds for the Central Universities · Natural Science Foundation of Guangdong Province · Program for New Century Excellent Talents in University

References (46)

Show source-provided references
1. McNutt · Science · 2013 · 342 · 141710.1126/science.1249481 ↗
2. Lu · Nature · 2017 · 543 · 72810.1038/nature21676 ↗
3. Weichselbaum · Nat. Rev. Clin Oncol. · 2017 · 14 · 36510.1038/nrclinonc.2016.211 ↗
4. Mujoo · Mol. Cancer Res. · 2018 · 16 · 120910.1158/1541-7786.MCR-17-0743 ↗
5. Ni · Nat. Commun. · 2018 · 9 · 235110.1038/s41467-018-04703-w ↗
6. Reynders · Cancer Treat. Rev. · 2015 · 41 · 50310.1016/j.ctrv.2015.03.011 ↗
7. Shi · Cancer Biol. Ther. · 2017 · 18 · 13710.1080/15384047.2016.1276133 ↗
8. Hiniker · N. Engl. J. Med. · 2012 · 366 · 203510.1056/NEJMc1203984 ↗
9. Postow · N. Engl. J. Med. · 2012 · 366 · 92510.1056/NEJMoa1112824 ↗
10. Page · Annu. Rev. Med. · 2014 · 65 · 18510.1146/annurev-med-092012-112807 ↗
11. Siva · Cancer Lett. · 2015 · 356 · 8210.1016/j.canlet.2013.09.018 ↗
12. Britschgi · Radiat. Oncol. · 2018 · 13 · 10210.1186/s13014-018-1049-3 ↗
13. Dewan · Clin. Cancer Res. · 2009 · 15 · 537910.1158/1078-0432.CCR-09-0265 ↗
14. Demaria · Clin. Cancer Res. · 2005 · 11 · 72810.1158/1078-0432.728.11.2 ↗
15. Tang · Cancer Immunol. Res. · 2014 · 2 · 83110.1158/2326-6066.CIR-14-0069 ↗
16. Laprise-Pelletier · Adv. Healthc. Mater. · 2018 · 7 · e170146010.1002/adhm.201701460 ↗
17. Meng · Int. J. Cancer · 2005 · 116 · 99210.1002/ijc.21131 ↗
18. Mason · Front. Oncol. · 2012 · 2 · 10110.3389/fonc.2012.00101 ↗
19. Vanpouille-Box · Vaccine · 2015 · 33 · 741510.1016/j.vaccine.2015.05.105 ↗
20. Min · Nat. Nanotechnol. · 2017 · 12 · 87710.1038/nnano.2017.113 ↗
21. Chen · Adv. Mater. · 2019 · e180222810.1002/adma.201802228 ↗
22. Pardoll · Nat. Rev. Cancer · 2012 · 12 · 25210.1038/nrc3239 ↗
23. Li · J. Hematol. Oncol. · 2018 · 11 · 4410.1186/s13045-018-0591-7 ↗
24. Manfredi · Lancet Oncol. · 2017 · 18 · 56110.1016/S1470-2045(17)30188-2 ↗
25. Dimitriou · J. Immunother. · 2019 · 42 · 2910.1097/CJI.0000000000000236 ↗
26. Mushti · Clin. Cancer Res. · 2018 · 24 · 226810.1158/1078-0432.CCR-17-1902 ↗
27. Meng · ACS Nano · 2018 · 12 · 830810.1021/acsnano.8b03590 ↗
28. Chen · Nanoscale · 2017 · 9 · 1482610.1039/C7NR05316A ↗
29. Li · Front. Immunol. · 2018 · 9 · 159110.3389/fimmu.2018.01591 ↗
30. Song · ACS Nano · 2016 · 10 · 63310.1021/acsnano.5b06779 ↗
31. Postow · N. Engl. J. Med. · 2018 · 378 · 15810.1056/NEJMra1703481 ↗
32. Gao · Adv. Mater. · 2017 · 29 · 201701429
33. Zhang · Biomaterials · 2017 · 138 · 1310.1016/j.biomaterials.2017.05.025 ↗
34. Graham · Int. J. Nanomed. · 2018 · 13 · 604910.2147/IJN.S140462 ↗
35. Mueller · J. Controlled Release · 2012 · 162 · 15910.1016/j.jconrel.2012.06.015 ↗
36. Buhtoiarov · Immunology · 2011 · 132 · 22610.1111/j.1365-2567.2010.03357.x ↗
37. Zhang · Proc. Natl. Acad. Sci. U. S. A. · 2015 · 112 · E6129
38. Zhang · Adv. Mater. · 2018 · 30 · 201705350
39. Zhang · Nano Today · 2017 · 13 · 710.1016/j.nantod.2016.10.008 ↗
40. Dehaini · Adv. Mater. · 2017 · 29 · 20160620910.1002/adma.201606209 ↗
41. Hu · Nat. Nanotechnol. · 2013 · 8 · 33610.1038/nnano.2013.54 ↗
42. Hu · Proc. Natl. Acad. Sci. U. S. A. · 2011 · 108 · 1098010.1073/pnas.1106634108 ↗
43. Krieg · Nat. Rev. Drug Discovery · 2006 · 5 · 47110.1038/nrd2059 ↗
44. Wolfers · Nat. Med. · 2001 · 7 · 29710.1038/85438 ↗
45. Zhou · Theranostics · 2016 · 6 · 101210.7150/thno.15095 ↗
46. Zhang · Nano Lett. · 2018 · 18 · 190810.1021/acs.nanolett.7b05263 ↗